A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides

Volume 321:1784-1790		December 28, 1989		Number 26

A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides

FJ Kaye, PA Bunn, SM Steinberg, JL Stocker, DC Ihde, AB Fischmann, EJ Glatstein, GP Schechter, RM Phelps, FM Foss, and et al.

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Abstract

Mycosis fungoides is a T-cell lymphoma that arises in the skin and progresses at highly variable rates. Nonradomized studies have suggested that early aggressive therapy may improve the prognosis in this usually fatal disease. We studied 103 patients with mycosis fungoides, who, after complete staging, were randomly assigned to receive either combination therapy, consisting of 3000 cGy of electron-beam radiation to the skin combined with parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine (n = 52) or sequential topical treatment (n = 51). The prognostic factors were well balanced in the two groups. Combined therapy produced considerable toxicity: 12 patients required hospitalization for fever and transient neutropenia, 5 had congestive heart failure, and 2 were later found to have acute nonlymphocytic leukemia. Patients receiving combined therapy had a significantly higher rate of complete response, documented by biopsy, than patients receiving conservative therapy (38 percent vs. 18 percent; P = 0.032). After a median follow-up of 75 months, however, there was no significant difference between the treatment groups in disease-free or overall survival. We conclude that early aggressive therapy with radiation and chemotherapy does not improve the prognosis for patients with mycosis fungoides as compared with conservative treatment beginning with sequential topical therapies.

Source Information

National Cancer Institute-Navy Medical Oncology Branch, Bethesda, Md 20814.

This article has been cited by other articles:

Prince, H. M., Whittaker, S., Hoppe, R. T. (2009). How I treat mycosis fungoides and Sezary syndrome. Blood 114: 4337-4353 [Abstract] [Full Text]
Quereux, G., Marques, S., Nguyen, J.-M., Bedane, C., D'incan, M., Dereure, O., Puzenat, E., Claudy, A., Martin, L., Joly, P., Delaunay, M., Beylot-Barry, M., Vabres, P., Celerier, P., Sasolas, B., Grange, F., Khammari, A., Dreno, B. (2008). Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sezary Syndrome. Arch Dermatol 144: 727-733 [Abstract] [Full Text]
Sterry, W., Heinzerling, L. (2008). Clinical Research in Cutaneous T-Cell Lymphoma Moving Forward. Arch Dermatol 144: 786-787 [Full Text]
Zinzani, P. L., Musuraca, G., Tani, M., Stefoni, V., Marchi, E., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Sabattini, E., Pileri, S., Baccarani, M. (2007). Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. JCO 25: 4293-4297 [Abstract] [Full Text]
Pulini, S., Rupoli, S., Goteri, G., Pimpinelli, N., Alterini, R., Tassetti, A., Scortechini, A. R., Offidani, M., Mulattieri, S., Stronati, A., Brandozzi, G., Giacchetti, A., Mozzicafreddo, G., Ricotti, G., Filosa, G., Bettacchi, A., Simonacci, M., Novelli, N., Leoni, P. (2007). Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. haematol 92: 686-689 [Abstract] [Full Text]
Sors, A., Jean-Louis, F., Pellet, C., Laroche, L., Dubertret, L., Courtois, G., Bachelez, H., Michel, L. (2006). Down-regulating constitutive activation of the NF-{kappa}B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107: 2354-2363 [Abstract] [Full Text]
Heinzerling, L., Kunzi, V., Oberholzer, P. A., Kundig, T., Naim, H., Dummer, R. (2005). Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106: 2287-2294 [Abstract] [Full Text]
Querfeld, C., Rosen, S. T., Kuzel, T. M., Kirby, K. A., Roenigk, H. H. Jr, Prinz, B. M., Guitart, J. (2005). Long-term Follow-up of Patients With Early-Stage Cutaneous T-Cell Lymphoma Who Achieved Complete Remission With Psoralen Plus UV-A Monotherapy. Arch Dermatol 141: 305-311 [Abstract] [Full Text]
Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., Rosenblad, E., Tjonnfjord, G., Wiklund, T., Osterborg, A. (2003). Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101: 4267-4272 [Abstract] [Full Text]
Demierre, M.-F., Vachon, L., Ho, V., Sutton, L., Cato, A., Leyland-Jones, B. (2003). Phase 1/2 Pilot Study of Methotrexate-Laurocapram Topical Gel for the Treatment of Patients With Early-Stage Mycosis Fungoides. Arch Dermatol 139: 624-628 [Abstract] [Full Text]
Toro, J. R., Liewehr, D. J., Pabby, N., Sorbara, L., Raffeld, M., Steinberg, S. M., Jaffe, E. S. (2003). Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101: 3407-3412 [Abstract] [Full Text]
Breneman, D., Duvic, M., Kuzel, T., Yocum, R., Truglia, J., Stevens, V. J. (2002). Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma. Arch Dermatol 138: 325-332 [Abstract] [Full Text]
Connors, J. M., Hsi, E. D., Foss, F. M. (2002). Lymphoma of the Skin. ASH Education Book 2002: 263-282 [Abstract] [Full Text]
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C. (2001). Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results. JCO 19: 2456-2471 [Abstract] [Full Text]
Duvic, M., Martin, A. G., Kim, Y., Olsen, E., Wood, G. S., Crowley, C. A., Yocum, R. C., for the Worldwide Bexarotene Study Group, (2001). Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma. Arch Dermatol 137: 581-593 [Abstract] [Full Text]
de Coninck, E. C., Kim, Y. H., Varghese, A., Hoppe, R. T. (2001). Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides. JCO 19: 779-784 [Abstract] [Full Text]
Dummer, R., Dobbeling, U., Geertsen, R., Willers, J., Burg, G., Pavlovic, J. (2001). Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. Blood 97: 523-527 [Abstract] [Full Text]
Siegel, R. S., Pandolfino, T., Guitart, J., Rosen, S., Kuzel, T. M. (2000). Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts. JCO 18: 2908-2925 [Abstract] [Full Text]
Guitart, J., Poiesz, B. J., Dube, D., Hutchison, R. (2000). HIV-1 and an HTLV-II-Associated Cutaneous T-Cell Lymphoma. NEJM 343: 303-304 [Full Text]
Clark, C., Dawe, R. S., Evans, A. T., Lowe, G., Ferguson, J. (2000). Narrowband TL-01 Phototherapy for Patch-Stage Mycosis Fungoides. Arch Dermatol 136: 748-752 [Abstract] [Full Text]
Parry, E. J., Stevens, S. R., Gilliam, A. C., Horvath, N., el-Charif, M., Spiro, T. P., Adler, L. P., Shina, D., Kinsella, T., Heyman, E. N., Cooper, K. D., Wood, G. S. (1999). Management of Cutaneous Lymphomas Using a Multidisciplinary Approach. Arch Dermatol 135: 907-911 [Full Text]
Diamandidou, E., Colome-Grimmer, M., Fayad, L., Duvic, M., Kurzrock, R. (1998). Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. Blood 92: 1150-1159 [Abstract] [Full Text]
Kern, D. E., Kidd, P. G., Moe, R., Hanke, D., Olerud, J. E. (1998). Analysis of T-Cell Receptor Gene Rearrangement in Lymph Nodes of Patients With Mycosis Fungoides: Prognostic Implications. Arch Dermatol 134: 158-164 [Abstract] [Full Text]
Luftl, M., Degitz, K., Plewig, G., Rocken, M. (1997). Psoralen Bath Plus UV-A Therapy: Possibilities and Limitations. Arch Dermatol 133: 1597-1603 [Abstract]
Willemze, R., Kerl, H., Sterry, W., Berti, E., Cerroni, L., Chimenti, S., Diaz-Perez, J.L., Geerts, M.L., Goos, M., Knobler, R., Ralfkiaer, E., Santucci, M., Smith, N., Wechsler, J., van Vloten, W.A., Meijer, C.J.L.M. (1997). EORTC Classification for Primary Cutaneous Lymphomas: A Proposal From the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90: 354-371 [Abstract] [Full Text]
Jones, G. W., Wilson;, L. D., Kurzrock, R., Diamandidou AUTHOR=Chui S., E. Ha AUTHOR= (1997). Mycosis Fungoides and Total Skin Electron Beam Radiation. Blood 89: 3062-3063 [Full Text]
Koh, H. K., Jacobson, J. O., Foss, F., Lew, R. A. (1995). Is Cutaneous T-Cell Lymphoma Curable?. Arch Dermatol 131: 1081-1082 [Abstract]
Marolleau, J. P., Baccard, M., Flageul, B., Rybojad, M., Laroche, L., Verola, O., Brandely, M., Morel, P., Gisselbrecht, C. (1995). High-Dose Recombinant Interleukin-2 in Advanced Cutaneous T-Cell Lymphoma. Arch Dermatol 131: 574-579 [Abstract]
Bunn, P. A. Jr (1995). Rational Therapy for Cutaneous T-Cell Lymphomas in the 1990s: Fact or Fancy?. Arch Dermatol 131: 603-605 [Abstract]
Licata, A. G., Wilson, L. D., Braverman, I. M., Feldman, A. M., Kacinski, B. M. (1995). Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation. Arch Dermatol 131: 432-435 [Abstract]
Schappell, D. L., Alper, J. C., McDonald, C. J. (1995). Treatment of Advanced Mycosis Fungoides and Sezary Syndrome With Continuous Infusions of Methotrexate Followed by Fluorouracil and Leucovorin Rescue. Arch Dermatol 131: 307-313 [Abstract]
Bunn, P A (1994). Cutaneous T cell lymphomas. BMJ 308: 551-552 [Full Text]
Cohen, J. H., Lessin, S. R., Vowels, B. R., Benoit, B., Witmer, W. K., Rook, A. H. (1993). The Sign of Leser-Trelat in Association With Sezary Syndrome: Simultaneous Disappearance of Seborrheic Keratoses and Malignant T-Cell Clone During Combined Therapy With Photopheresis and Interferon Alfa. Arch Dermatol 129: 1213-1215 [Abstract]
Ramsay, D. L., Lish, K. M., Yalowitz, C. B., Soter, N. A. (1992). Ultraviolet-B Phototherapy for Early-Stage Cutaneous T-cell Lymphoma. Arch Dermatol 128: 931-933 [Abstract]
Rook, A. H., Prystowsky, M. B., Cassin, M., Boufal, M., Lessin, S. R. (1991). Combined Therapy for Sezary Syndrome With Extracorporeal Photochemotherapy and Low-Dose Interferon Alfa Therapy: Clinical, Molecular, and Immunologic Observations. Arch Dermatol 127: 1535-1540 [Abstract]

Comments and questions? Please contact us.